--- title: "Artivion, Inc. (AORT.US)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/AORT.US.md" symbol: "AORT.US" name: "Artivion, Inc." industry: "Health Care Equipment" --- # Artivion, Inc. (AORT.US) | Item | Detail | |------|--------| | Industry | Health Care Equipment | | Location | US Market | | Website | [artivion.com](https://artivion.com) | ## Company Profile Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and... ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-14T04:30:12.000Z **Overall: B (0.37)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 20 / 184 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 13.59% | | | Net Profit YoY | 173.25% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 3.87 | | | Dividend Ratio | 0.00% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 1.73B | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 441.33M | | **Multi Score**: B #### Profit Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 2.70% | C | | Profit Margin | 2.21% | C | | Gross Margin | 64.40% | A | #### Growth Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 13.59% | B | | Net Profit YoY | 173.25% | A | | Total Assets YoY | 12.13% | B | | Net Assets YoY | 62.29% | A | #### Cash Score: A | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | 4518.12% | A | | OCF YoY | 13.59% | B | #### Operating Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.53 | C | #### Debt Score: C | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 49.34% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Artivion, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "C", "indicators": [ { "name": "ROE", "value": "2.70%", "rating": "C" }, { "name": "Profit Margin", "value": "2.21%", "rating": "C" }, { "name": "Gross Margin", "value": "64.40%", "rating": "A" } ] }, { "name": "Growth", "grade": "B", "indicators": [ { "name": "Revenue YoY", "value": "13.59%", "rating": "B" }, { "name": "Net Profit YoY", "value": "173.25%", "rating": "A" }, { "name": "Total Assets YoY", "value": "12.13%", "rating": "B" }, { "name": "Net Assets YoY", "value": "62.29%", "rating": "A" } ] }, { "name": "Cash", "grade": "A", "indicators": [ { "name": "Cash Flow Margin", "value": "4518.12%", "rating": "A" }, { "name": "OCF YoY", "value": "13.59%", "rating": "B" } ] }, { "name": "Operating", "grade": "C", "indicators": [ { "name": "Turnover", "value": "0.53", "rating": "C" } ] }, { "name": "Security", "grade": "C", "indicators": [ { "name": "Gearing Ratio", "value": "49.34%", "rating": "C" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | Inspire Medical (US.INSP) | A | B | A | A | B | A | | 02 | Delcath (US.DCTH) | C | A | A | A | A | A | | 03 | Intuitive Surgical (US.ISRG) | A | B | C | A | B | B | | 04 | Stryker (US.SYK) | A | B | C | C | B | B | | 05 | Boston Scientific (US.BSX) | B | B | E | A | B | B | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 179.26 | 40/181 | - | - | - | | PB | 3.91 | 87/181 | 4.94 | 4.67 | 3.91 | | PS (TTM) | 3.97 | 80/181 | 5.06 | 4.49 | 3.08 | | Dividend Yield | 0.00% | - | - | - | - | ## Institutional View ### Analyst Rating Distribution > As of 2026-02-13T05:00:00.000Z Total Analysts: **7** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 4 | 57% | | Overweight | 2 | 29% | | Hold | 1 | 14% | | Underweight | 0 | 0% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 36.60 | | Highest Target | 58.00 | | Lowest Target | 40.00 | ## References - [Company Overview](https://longbridge.com/en/quote/AORT.US/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/AORT.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/AORT.US/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.